<DOC>
	<DOCNO>NCT02713984</DOCNO>
	<brief_summary>Chimeric antigen receptor T cell ( CAR-T ) therapy yet fully explore solid tumor . Human epidermal growth factor receptor-2 ( HER2 ) widely express cancer . Investigators develop anti-HER2 CAR-modified T cell validate efficiency target HER2-positive cancer preclinical study . This study aim confirm adverse effect include cytokine storm response adverse effect . In addition , CAR-T cell persistence , tumor elimination disease status treatment evaluate .</brief_summary>
	<brief_title>A Clinical Research CAR T Cells Targeting HER2 Positive Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Relapsed refractory HER2 positive cancer . 2 . KPS &gt; 60 . 3 . Life expectancy &gt; 3 month . 4 . Gender unlimited , age 18 year 80 year . 5 . Assessable lesion minimum size 10mm CT scan MRI . 6 . Acceptable organ function Hematology : Absolute neutrophil count great 800/mm^3 without support filgrastim . White blood cell ( WBC ) ( &gt; 2000/mm^3 ) . Platelet count great 50,000/mm^3 . Hemoglobin great 9.0 g/dl . Chemistry : Serum alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) less equal 3 time upper limit normal ( patient without liver metastasis ) 6 time upper limit normal ( patient liver metastasis ) . Serum creatinine less equal 3 time upper limit normal Total bilirubin less equal 3 time upper limit normal . 7 . No serious disease ( autoimmune disease , immunodeficiency etc. ) . 8 . Adequate cardiac function ( LVEFâ‰¥40 % ) . 9 . No tumor . 10 . Patients volunteer participate research . 1 . Allergic cytokine . 2 . Uncontrolled active infection . 3 . Acute chronic GVHD . 4 . MODS . 5 . Treated T cell inhibitor . 6 . HIV affect . 7 . Other situation improper research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HER2 CAR-T</keyword>
	<keyword>safety</keyword>
	<keyword>efficiency</keyword>
	<keyword>refractory relapse cancer</keyword>
</DOC>